Halozyme Therapeutics reported $4.39M in Interest Expense on Debt for its fiscal quarter ending in June of 2025.


Interest Expense On Debt Change Date
Acadia Pharmaceuticals 0 4.12M Sep/2024
Agios Pharmaceuticals 3.01M 10.05M Dec/2024
Alnylam Pharmaceuticals USD 40.25M 1.6M Jun/2025
Amarin USD 3K 3K Dec/2024
Amgen USD 694M 29M Jun/2025
Baxter International USD 81M 19M Mar/2025
Cytokinetics USD 24.26M 1.32M Jun/2025
DBV Technologies 461K 323.71K Mar/2025
Eli Lilly USD 249M 5.3M Jun/2025
Halozyme Therapeutics USD 4.39M 131K Jun/2025
Ionis Pharmaceuticals USD 19M 0 Jun/2025
MannKind USD 6.19M 4.44M Jun/2025
Pfizer USD 654M 0 Jun/2025
United Therapeutics USD 7.3M 1.2M Jun/2025